Amryt Pharma has been granted a patent for a method of administering oral octreotide therapy to female subjects, requiring contraception. The method involves administering a specific oral dosage form and counseling against the use of combined oral contraceptives. GlobalData’s report on Amryt Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Amryt Pharma Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Amryt Pharma, was a key innovation area identified from patents. Amryt Pharma's grant share as of February 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Oral octreotide therapy method without combined oral contraceptives

Source: United States Patent and Trademark Office (USPTO). Credit: Amryt Pharma Plc

A recently granted patent (Publication Number: US11890316B2) discloses a method for administering oral octreotide to female subjects in need of a contraceptive method. The method involves administering an oral dosage form containing octreotide and a medium chain fatty acid salt, along with counseling the subject to avoid using a combined oral contraceptive. The composition comprises 12% to 21% by weight of the medium chain fatty acid salt, and the subject is advised to opt for alternative contraceptive methods to avoid potential interactions.

Furthermore, the patent also covers scenarios where the female subject is already using a combined oral contraceptive. In such cases, the subject is counseled to use a back-up method of contraception or switch to an alternative non-hormonal method. The method aims to ensure the effective administration of oral octreotide while managing contraceptive needs. The composition of the oral dosage form includes specific percentages of the medium chain fatty acid salt, and the subject is advised on appropriate contraceptive choices to optimize treatment outcomes.

To know more about GlobalData’s detailed insights on Amryt Pharma, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies